Xinxin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xinxin Chen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Lei Chen
The Affiliated Suzhou Hospital of Nanjing Medical University
4 shared publications Qiong Shen
Department of Endocrinology, The Affiliated Suzhou Hospital of Nanjing Medical University, 26 Daoqian Road, Suzhou, 215000, People's Republic of China
4 shared publications- Shu Wang
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025
4 shared publications Huanhuan Zang
The Affiliated Suzhou Hospital of Nanjing Medical University
3 shared publicationsXiangguo Cong
Department of Endocrinology, The Affiliated Suzhou Hospital of Nanjing Medical University, 26 Daoqian Road, Suzhou, 215000, People's Republic of China
3 shared publicationsYing Wu
Department of Endocrinology, The Affiliated Suzhou Hospital of Nanjing Medical University, 26 Daoqian Road, Suzhou, 215000, People's Republic of China
3 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Lipid profiles and risk of gestational diabetes mellitus in women with isolated TPOAb positivity during early pregnancy
Isolated thyroid peroxidative antibody (TPOAb) positivity has been linked to adverse pregnancy outcomes including gestational diabetes mellitus (GDM). Elevated lipids are reported as pivotal risk factors. Current researches indicated 75 g oral glucose tolerance test (OGTT) in early pregnancy has limited predictive ability for GDM. The lipid profiles in isolated TPOAb positive pregnant women and their correlation with GDM were unclear. To delineate the specific lipid profile characteristics in pregnant women with isolated TPOAb positivity and to identify potential lipid biomarkers for early prediction of GDM. Euthyroid pregnant women were enrolled in the first trimester and underwent OGTT in the second trimester. Participants were divided into four groups based on TPOAb status and OGTT results. Untargeted liquid chromatography-mass spectrometry (LC-MS) was used to identify lipid molecules. Of 88 women, 43.5% (20/46) with TPOAb positivity and 35.7% (15/42) without were diagnosed with GDM. Low-density lipoprotein (LDL) levels were positively associated with GDM risk in TPOAb positive women. LC-MS analysis identified 13 different lipid molecules significantly correlated with OGTT results. A nomogram was constructed to predict the occurrence of GDM. Elevated first-trimester LDL levels are associated with increased GDM risk in isolated TPOAb-positive women. Furthermore, PC (20:0/16:0) and TG (16:0/16:0/18:1), combined with TSH and TPOAb titers, are potential biomarkers for early prediction of GDM in this specific population.
- 19 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessLipid profiles and risk of gestational diabetes mellitus in women with isolated TPOAb positivity during early pregnancy
Isolated thyroid peroxidative antibody (TPOAb) positivity has been linked to adverse pregnancy outcomes including gestational diabetes mellitus (GDM). Elevated lipids are reported as pivotal risk factors. Current researches indicated 75 g oral glucose tolerance test (OGTT) in early pregnancy has limited predictive ability for GDM. The lipid profiles in isolated TPOAb positive pregnant women and their correlation with GDM were unclear. To delineate the specific lipid profile characteristics in pregnant women with isolated TPOAb positivity and to identify potential lipid biomarkers for early prediction of GDM. Euthyroid pregnant women were enrolled in the first trimester and underwent OGTT in the second trimester. Participants were divided into four groups based on TPOAb status and OGTT results. Untargeted liquid chromatography-mass spectrometry (LC-MS) was used to identify lipid molecules. Of 88 women, 43.5% (20/46) with TPOAb positivity and 35.7% (15/42) without were diagnosed with GDM. Low-density lipoprotein (LDL) levels were positively associated with GDM risk in TPOAb positive women. LC-MS analysis identified 13 different lipid molecules significantly correlated with OGTT results. A nomogram was constructed to predict the occurrence of GDM. Elevated first-trimester LDL levels are associated with increased GDM risk in isolated TPOAb-positive women. Furthermore, PC (20:0/16:0) and TG (16:0/16:0/18:1), combined with TSH and TPOAb titers, are potential biomarkers for early prediction of GDM in this specific population.
- Open Access
- 30 April 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (4)
A case of unexpected thyroid storm in postpartum
Thyroid storm is a rare and serious endocrine crisis during the perinatal period and typically occurs in patients with Graves’ disease. We present the case of a postpartum woman without prior history of thyroid disease who presented with vomiting, fever, irregular abdominal pain, and a diagnosis of intrauterine death. Despite comprehensive treatment, she showed persistent tachycardia, fever, and multi-organ failure. Diagnostic assessment revealed elevated thyroid hormone levels, and she was diagnosed with thyroid storm based on the scoring system of Burch–Wartofsky and the Japanese Thyroid Association diagnostic criteria. Treatment included plasmapheresis, β-blockers, iodine solutions, antithyroid drugs, and corticosteroids. Following successful mitigation of thyroid storm, she developed hypothyroidism and was treated with levothyroxine. For patients with no history of thyroid disease or negative thyroid autoantibodies, especially postpartum women, presenting unexplained symptoms such as tachycardia, fever, diarrhea, sweating, and altered consciousness, the possibility of thyroid storm should be considered.
- 30 April 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (4)
Open AccessA case of unexpected thyroid storm in postpartum
Thyroid storm is a rare and serious endocrine crisis during the perinatal period and typically occurs in patients with Graves’ disease. We present the case of a postpartum woman without prior history of thyroid disease who presented with vomiting, fever, irregular abdominal pain, and a diagnosis of intrauterine death. Despite comprehensive treatment, she showed persistent tachycardia, fever, and multi-organ failure. Diagnostic assessment revealed elevated thyroid hormone levels, and she was diagnosed with thyroid storm based on the scoring system of Burch–Wartofsky and the Japanese Thyroid Association diagnostic criteria. Treatment included plasmapheresis, β-blockers, iodine solutions, antithyroid drugs, and corticosteroids. Following successful mitigation of thyroid storm, she developed hypothyroidism and was treated with levothyroxine. For patients with no history of thyroid disease or negative thyroid autoantibodies, especially postpartum women, presenting unexplained symptoms such as tachycardia, fever, diarrhea, sweating, and altered consciousness, the possibility of thyroid storm should be considered.
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Lipids
- Vol. 2024 (1) , 5589492
Lipid Metabolism in Pregnancy Women with Hypothyroidism and Potential Influence on Pregnancy Outcome
Thyroid hormone (TH) is essential for maintaining normal physiological processes during pregnancy, including the metabolism of energy materials in both the mother and fetus and the growth and development of fetal bone and nervous system. TH can act on the liver, fat, and other tissues and organs to participate in lipid synthesis and breakdown through multiple pathways. Consequently, abnormal thyroid function is often accompanied by lipid metabolism disorders. Both clinical and subclinical hypothyroidism, as well as dyslipidemia during pregnancy, have been shown to be associated with an increased risk of multiple adverse pregnancy outcomes. Recently, there has been an increased interest in studying the alteration of lipidomic and hypothyroidism (both clinical and subclinical hypothyroidism) during pregnancy. Studies have suggested that altered lipid molecules might be used as potential biomarker and associated with adverse maternal and neonatal outcome. Thus, we summarized the associations between lipid metabolism and clinical or subclinical hypothyroidism during pregnancy in this review. Then, we discussed the underlying mechanisms of thyroid dysfunction and lipid metabolism. In addition, we reviewed the possible effect of dyslipidemia on pregnancy and neonatal outcome. However, the relationship between hypothyroidism during pregnancy and changes in the lipid profile and how to intervene in the occurrence and development of adverse pregnancy outcomes require further study.
- 1 January 2024
- Published by Wiley in Journal of Lipids
- Vol. 2024 (1) , 5589492
Open AccessLipid Metabolism in Pregnancy Women with Hypothyroidism and Potential Influence on Pregnancy Outcome
Thyroid hormone (TH) is essential for maintaining normal physiological processes during pregnancy, including the metabolism of energy materials in both the mother and fetus and the growth and development of fetal bone and nervous system. TH can act on the liver, fat, and other tissues and organs to participate in lipid synthesis and breakdown through multiple pathways. Consequently, abnormal thyroid function is often accompanied by lipid metabolism disorders. Both clinical and subclinical hypothyroidism, as well as dyslipidemia during pregnancy, have been shown to be associated with an increased risk of multiple adverse pregnancy outcomes. Recently, there has been an increased interest in studying the alteration of lipidomic and hypothyroidism (both clinical and subclinical hypothyroidism) during pregnancy. Studies have suggested that altered lipid molecules might be used as potential biomarker and associated with adverse maternal and neonatal outcome. Thus, we summarized the associations between lipid metabolism and clinical or subclinical hypothyroidism during pregnancy in this review. Then, we discussed the underlying mechanisms of thyroid dysfunction and lipid metabolism. In addition, we reviewed the possible effect of dyslipidemia on pregnancy and neonatal outcome. However, the relationship between hypothyroidism during pregnancy and changes in the lipid profile and how to intervene in the occurrence and development of adverse pregnancy outcomes require further study.
- Open Access
- 23 January 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-6
DRESS/DiHS syndrome induced by Propylthiouracil: a case report
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as Drug-induced hypersensitivity syndrome (DiHS), is a severe adverse drug reaction. Propylthiouracil, a member of thiouracils group, is widely used in medical treatment of hyperthyroidism. Propylthiouracil is associated with multiple adverse effects such as rash, agranulocytosis hepatitis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, but rarely triggers DRESS/DiHS syndrome. Here, we describe a severe case of propylthiouracil-induced DRESS/DiHS syndrome. Case presentation: A 38-year-old female was treated with methimazole for hyperthyroidism at first. 4 weeks later, the patient developed elevated liver transaminase so methimazole was stopped. After liver function improved in 2 weeks, medication was switched to propylthiouracil therapy. The patient subsequently developed nausea and rash followed by a high fever, acute toxic hepatitis and multiple organ dysfunction (liver, lung and heart), which lasted for 1 month after propylthiouracil was started. According to the diagnostic criteria, the patient was diagnosed of DRESS/DiHS syndrome which was induced by propylthiouracil. As a result, propylthiouracil was immediately withdrawn. And patient was then treated with adalimumab, systematic corticosteroids and plasmapheresis in sequence. Symptoms were finally resolved 4 weeks later. Conclusions: Propylthiouracil is a rare cause of the DRESS/DiHS syndrome, which typically consists of severe dermatitis and various degrees of internal organ involvement. We want to emphasize through this severe case that DRESS/DiHS syndrome should be promptly recognized to hasten recovery.
- 23 January 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-6
Open AccessDRESS/DiHS syndrome induced by Propylthiouracil: a case report
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as Drug-induced hypersensitivity syndrome (DiHS), is a severe adverse drug reaction. Propylthiouracil, a member of thiouracils group, is widely used in medical treatment of hyperthyroidism. Propylthiouracil is associated with multiple adverse effects such as rash, agranulocytosis hepatitis and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, but rarely triggers DRESS/DiHS syndrome. Here, we describe a severe case of propylthiouracil-induced DRESS/DiHS syndrome. Case presentation: A 38-year-old female was treated with methimazole for hyperthyroidism at first. 4 weeks later, the patient developed elevated liver transaminase so methimazole was stopped. After liver function improved in 2 weeks, medication was switched to propylthiouracil therapy. The patient subsequently developed nausea and rash followed by a high fever, acute toxic hepatitis and multiple organ dysfunction (liver, lung and heart), which lasted for 1 month after propylthiouracil was started. According to the diagnostic criteria, the patient was diagnosed of DRESS/DiHS syndrome which was induced by propylthiouracil. As a result, propylthiouracil was immediately withdrawn. And patient was then treated with adalimumab, systematic corticosteroids and plasmapheresis in sequence. Symptoms were finally resolved 4 weeks later. Conclusions: Propylthiouracil is a rare cause of the DRESS/DiHS syndrome, which typically consists of severe dermatitis and various degrees of internal organ involvement. We want to emphasize through this severe case that DRESS/DiHS syndrome should be promptly recognized to hasten recovery.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 12
The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease
The bioassay of thyroid-stimulating immunoglobulin was reported to have a similar performance to the commonly used thyroid-stimulating hormone binding inhibition assay, also known as thyroid receptor antibody assay. The normal reference range of thyroid receptor antibody levels indicates the withdrawal of anti-thyroid drugs in the recent clinical guidelines. A prospective, longitudinal observational study was conducted to evaluate the prognostic value of thyroid-stimulating immunoglobulin in patients with Graves’ disease. A total of 77 patients with Graves’ disease treated with anti-thyroid drugs were in a continuous follow-up until 1 year after anti-thyroid drugs discontinuation. Commercial kits of thyroid-stimulating immunoglobulin and M22-thyroid-stimulating hormone binding inhibition assay were used and compared. Thyroid-stimulating immunoglobulin was all negative in healthy controls, Hashimoto thyroiditis, and subacute thyroiditis. Thyroid-stimulating immunoglobulin value was highest in untreated patients with Graves’ disease (p < 0.001). Under anti-thyroid drugs treatment, thyroid-stimulating immunoglobulin value decreased gradually. A total of 21 patients had positive thyroid-stimulating immunoglobulin at the end of treatment. According to clinical fate of patients with Graves’ disease after withdrawal of anti-thyroid drugs, thyroid-stimulating immunoglobulin value and positivity in patients with relapse were significantly higher than that reported in patients with remission (p = 0.001, p < 0.001). After adjustment for age, gender, initial thyroid receptor antibody, initial thyroid-stimulating immunoglobulin, and thyroid receptor antibody at the end of treatment, the odds ratio of positive thyroid-stimulating immunoglobulin for the risk of relapse was 33.271 (95% confidence interval: 4.741–233.458, p < 0.001) and odds ratio of quantitative thyroid-stimulating immunoglobulin was 1.009 (95% confidence interval: 1.002–1.015, p < 0.001). Thyroid-stimulating immunoglobulin is a good predictor of relapse in patients with Graves’ disease treated with anti-thyroid drugs. It might be safer to discontinue anti-thyroid drugs when thyroid-stimulating immunoglobulin and thyroid receptor antibody were both negative.
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 12
Open AccessThe prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease
The bioassay of thyroid-stimulating immunoglobulin was reported to have a similar performance to the commonly used thyroid-stimulating hormone binding inhibition assay, also known as thyroid receptor antibody assay. The normal reference range of thyroid receptor antibody levels indicates the withdrawal of anti-thyroid drugs in the recent clinical guidelines. A prospective, longitudinal observational study was conducted to evaluate the prognostic value of thyroid-stimulating immunoglobulin in patients with Graves’ disease. A total of 77 patients with Graves’ disease treated with anti-thyroid drugs were in a continuous follow-up until 1 year after anti-thyroid drugs discontinuation. Commercial kits of thyroid-stimulating immunoglobulin and M22-thyroid-stimulating hormone binding inhibition assay were used and compared. Thyroid-stimulating immunoglobulin was all negative in healthy controls, Hashimoto thyroiditis, and subacute thyroiditis. Thyroid-stimulating immunoglobulin value was highest in untreated patients with Graves’ disease (p < 0.001). Under anti-thyroid drugs treatment, thyroid-stimulating immunoglobulin value decreased gradually. A total of 21 patients had positive thyroid-stimulating immunoglobulin at the end of treatment. According to clinical fate of patients with Graves’ disease after withdrawal of anti-thyroid drugs, thyroid-stimulating immunoglobulin value and positivity in patients with relapse were significantly higher than that reported in patients with remission (p = 0.001, p < 0.001). After adjustment for age, gender, initial thyroid receptor antibody, initial thyroid-stimulating immunoglobulin, and thyroid receptor antibody at the end of treatment, the odds ratio of positive thyroid-stimulating immunoglobulin for the risk of relapse was 33.271 (95% confidence interval: 4.741–233.458, p < 0.001) and odds ratio of quantitative thyroid-stimulating immunoglobulin was 1.009 (95% confidence interval: 1.002–1.015, p < 0.001). Thyroid-stimulating immunoglobulin is a good predictor of relapse in patients with Graves’ disease treated with anti-thyroid drugs. It might be safer to discontinue anti-thyroid drugs when thyroid-stimulating immunoglobulin and thyroid receptor antibody were both negative.
- Open Access
- 25 September 2019
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (AHEAD) , 52-58
Relationship of gender and age on thyroid hormone parameters in a large Chinese population
Key words: Thyroid hormone; thyrotropin (TSH; Gender and age; Chinese population
- 25 September 2019
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (AHEAD) , 52-58
Open AccessRelationship of gender and age on thyroid hormone parameters in a large Chinese population
Key words: Thyroid hormone; thyrotropin (TSH; Gender and age; Chinese population
- Open Access
- 23 January 2019
- Published by Brieflands in International Journal of Endocrinology and Metabolism
- Vol. In Press (In Press) , e66450
Age and Gender Specific Thyroid Hormones and Their Relationships with Body Mass Index in a Large Chinese Population: A Clinical Trial
International Journal of Endocrinology and Metabolism
- 23 January 2019
- Published by Brieflands in International Journal of Endocrinology and Metabolism
- Vol. In Press (In Press) , e66450
Open AccessAge and Gender Specific Thyroid Hormones and Their Relationships with Body Mass Index in a Large Chinese Population: A Clinical Trial
International Journal of Endocrinology and Metabolism
- Open Access
- 5 July 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 188
Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves’ disease
Abnormal microRNAs (miRNAs) were reported to be involved in the mechanism of Graves’ disease (GD). Dysregulated miRNAs may be overlapping in different cells and can be secreted to circulation. We chose miRNAs which were previously reported to be differentially expressed in peripheral blood mononuclear cells (PBMCs) in patients with GD with different disease stage, detected the expression of those miRNAs in serum, corroborated the findings in thyroid tissue, and validated the target gene in vitro to investigate the possible role of circulating miRNAs in GD. A total of 54 individuals with untreated GD, 12 individuals with GD in remission and 14 disease-free controls were enrolled. The expression of miR-142-3p, miR-154-3p, miR-431-3p, miR-590-5p, and let-7b was detected in the serum. Ten thyroid tissue samples from patients with GD and six disease-free thyroid samples were used for further validation. The potential target genes were identified and validated in vitro. miR-142-3p, miR-154-3p, miR-431-3p, miR-590-5p, and let-7b were present in serum and two of them (miR-142-3p and let-7b) were significantly increased in serum of patients with untreated GD (for serum miR-142-3p, P = 0.033, for serum let-7b, P = 0.026) and gradually decreased to normal levels in patients with GD in remission. Correlation analysis showed that let-7b level was strongly correlated with TRAb level (r = 0.305, P = 0.001). let-7b directly inhibited promyelocytic leukemia zinc finger (PLZF) expression and increased the expression of TSHR in thyroid cells in vitro. Furthermore, let-7b levels in GD thyroid tissue were found to be inversely correlated with PLZF levels (r = − 0.849, P = 0.033). Decreased PLZF and increased TSHR was validated in thyroid tissue in patients with GD. The present study confirmed that a portion of miRNAs in PBMCs were also presented and differentially expressed in serum and thyroid tissue. Upregulated in all these three compartments, let-7b may be used as a disease biomarker and therapeutic targets in patients with GD. Circulating let-7b had a strong correlation with disease severity and let-7b may participate in the production of TRAb via targeting PLZF in patients with GD.
- 5 July 2018
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 188
Open AccessSerum and thyroid tissue level of let-7b and their correlation with TRAb in Graves’ disease
Abnormal microRNAs (miRNAs) were reported to be involved in the mechanism of Graves’ disease (GD). Dysregulated miRNAs may be overlapping in different cells and can be secreted to circulation. We chose miRNAs which were previously reported to be differentially expressed in peripheral blood mononuclear cells (PBMCs) in patients with GD with different disease stage, detected the expression of those miRNAs in serum, corroborated the findings in thyroid tissue, and validated the target gene in vitro to investigate the possible role of circulating miRNAs in GD. A total of 54 individuals with untreated GD, 12 individuals with GD in remission and 14 disease-free controls were enrolled. The expression of miR-142-3p, miR-154-3p, miR-431-3p, miR-590-5p, and let-7b was detected in the serum. Ten thyroid tissue samples from patients with GD and six disease-free thyroid samples were used for further validation. The potential target genes were identified and validated in vitro. miR-142-3p, miR-154-3p, miR-431-3p, miR-590-5p, and let-7b were present in serum and two of them (miR-142-3p and let-7b) were significantly increased in serum of patients with untreated GD (for serum miR-142-3p, P = 0.033, for serum let-7b, P = 0.026) and gradually decreased to normal levels in patients with GD in remission. Correlation analysis showed that let-7b level was strongly correlated with TRAb level (r = 0.305, P = 0.001). let-7b directly inhibited promyelocytic leukemia zinc finger (PLZF) expression and increased the expression of TSHR in thyroid cells in vitro. Furthermore, let-7b levels in GD thyroid tissue were found to be inversely correlated with PLZF levels (r = − 0.849, P = 0.033). Decreased PLZF and increased TSHR was validated in thyroid tissue in patients with GD. The present study confirmed that a portion of miRNAs in PBMCs were also presented and differentially expressed in serum and thyroid tissue. Upregulated in all these three compartments, let-7b may be used as a disease biomarker and therapeutic targets in patients with GD. Circulating let-7b had a strong correlation with disease severity and let-7b may participate in the production of TRAb via targeting PLZF in patients with GD.
- 1 August 2016
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 94 (8) , 895-899
Assessment of 25 CYP2D6 alleles found in the Chinese population on propafenone metabolism in vitro
Cytochrome P450 enzyme 2D6 (CYP2D6) is an important member of the cytochrome P450 enzyme superfamily, with more than 100 CYP2D6 allelic variants being previously reported. The aim of this study was to assess the catalytic characteristics of 25 alleles (CYP2D6.1 and 24 CYP2D6 variants) and their effects on the metabolism of propafenone in vitro. Twenty-five CYP2D6 alleles were expressing in 21 Spodoptera frugiperda (Sf) insect cells, and each variant was evaluated using propafenone as the substrate. Reactions were performed at 37 °C with 1–100 μmol/L propafenone for 30 min. After termination, the product 5-OH-propafenone was extracted and used for signal collection by ultra-performance liquid chromatography (UPLC). Compared with wild type CYP2D6.1, the intrinsic clearance (Vmax and Km) values of all variants were significantly altered. Three variants (CYP2D6.87, CYP2D6.90, CYP2D6.F219S) exhibited markedly increased intrinsic clearance values (129% to 165%), whereas 21 variants exhibited significantly decreased values (16% to 85%) due to increased Km and (or) decreased Vmax values. These results indicated that the majority of tested alleles had significantly altered catalytic activity towards propafenone hydroxylation in this expression system. Attention should be paid to subjects carrying these rare alleles when treated with propafenone.
- 1 August 2016
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 94 (8) , 895-899
Assessment of 25 CYP2D6 alleles found in the Chinese population on propafenone metabolism in vitro
Cytochrome P450 enzyme 2D6 (CYP2D6) is an important member of the cytochrome P450 enzyme superfamily, with more than 100 CYP2D6 allelic variants being previously reported. The aim of this study was to assess the catalytic characteristics of 25 alleles (CYP2D6.1 and 24 CYP2D6 variants) and their effects on the metabolism of propafenone in vitro. Twenty-five CYP2D6 alleles were expressing in 21 Spodoptera frugiperda (Sf) insect cells, and each variant was evaluated using propafenone as the substrate. Reactions were performed at 37 °C with 1–100 μmol/L propafenone for 30 min. After termination, the product 5-OH-propafenone was extracted and used for signal collection by ultra-performance liquid chromatography (UPLC). Compared with wild type CYP2D6.1, the intrinsic clearance (Vmax and Km) values of all variants were significantly altered. Three variants (CYP2D6.87, CYP2D6.90, CYP2D6.F219S) exhibited markedly increased intrinsic clearance values (129% to 165%), whereas 21 variants exhibited significantly decreased values (16% to 85%) due to increased Km and (or) decreased Vmax values. These results indicated that the majority of tested alleles had significantly altered catalytic activity towards propafenone hydroxylation in this expression system. Attention should be paid to subjects carrying these rare alleles when treated with propafenone.